<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Physiology Anatomy and Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7BB1FCBA-BC86-4DE3-9404-E41BB4849178"><gtr:id>7BB1FCBA-BC86-4DE3-9404-E41BB4849178</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Beeson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/95DF1C05-09A0-412A-87F2-6D0A6175BFD7"><gtr:id>95DF1C05-09A0-412A-87F2-6D0A6175BFD7</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500822"><gtr:id>8759A796-F569-4EBB-BA2B-EB780B2190ED</gtr:id><gtr:title>RNA interference as a therapeutic agent for neuromuscular disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500822</gtr:grantReference><gtr:abstractText>In many dominant genetic diseases the mutant gene that gives rise to the disease co-exists with a normal copy of the gene, frequently only differing from the normal copy by a single letter (nucleotide base) in its genetic code. Any method that was reliably able to discriminate the mutant copy of the gene from the normal copy (i.e. that was sensitive enough to discriminate as little as a single base difference), and destroy it, thereby leaving only normal copies of the gene present, would have great potential as a novel treatment strategy. Such a method now exists based on a powerful new technology called RNA interference (RNAi). We have studied dominant mutations in the muscle acetylcholine receptor (AChR) gene (that codes for an important neurotransmitter receptor essential for normal functioning of the nerve-muscle junction) that cause a disease called slow channel myasthenic syndrome. In this work we have demonstrated proof-of-concept for using RNAi to selectively silence expression of the mutant AChR genes. We now wish to develop further this very promising approach by; studying and optimizing the RNAi sequence and chemical structure for mutant gene silencing; testing these in muscle cell lines derived from patients with this disorder; investigating the parameters for effective and safe delivery of RNAi molecules to the nerve-muscle junction; and finally undertaking trials of this therapy in animals.</gtr:abstractText><gtr:technicalSummary>RNA interference (RNAi) is a powerful new method for gene silencing. We have demonstrated proof-of-principle for allele-specific gene silencing using RNAi, which offers a novel therapeutic approach for treating dominant genetic neurological disorders. We also have encouraging preliminary data on siRNA delivery to muscle in vivo. We therefore hypothesize that selective down regulation of mutant genes associated with neuromuscular junction (NMJ) disease is very likely to lessen the symptoms as well as slow the progression of the disease. This project will systematically investigate specific silencing of pathogenic mutant acetylcholine receptor (AChR) subunits that underlie the neuromuscular disorder, slow channel congenital myasthenic syndrome (SCCMS). We will identify highly potent RNAi molecules designed specifically to down regulate expression of genes associated with SCCMS; optimize the specific silencing of mutant AChR alleles in patient muscle cell lines; investigate and optimize RNAi delivery to the NMJ in vivo (testing both local and systemic RNAi delivery with chemically modified RNAi molecules and using viral expression and delivery); and conduct preclinical studies in a relevant animal model to evaluate its potential for correcting synaptic dysfunction. The ultimate goal of the research programme is to identify effective and safe candidate molecules and delivery systems for clinical application.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>204932</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>MDEX CONSORTIUM</gtr:description><gtr:id>E3FA9ACA-28E8-4A40-A911-41AD1D81E29B</gtr:id><gtr:impact>19713152</gtr:impact><gtr:outcomeId>eGB7vdjXwzf-1</gtr:outcomeId><gtr:partnerContribution>New avenues for experimental work</gtr:partnerContribution><gtr:piContribution>Pre-clinical evaluation of oligonucleotides for muscular dystrophy therapy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Gait collaboration</gtr:description><gtr:id>649F92E3-2F78-4163-8F64-0D70E13A5387</gtr:id><gtr:impact>18776238 
21062902
20068555
18842625</gtr:impact><gtr:outcomeId>C7BA63CE013-1</gtr:outcomeId><gtr:partnerContribution>Materials</gtr:partnerContribution><gtr:piContribution>In vivo work, miRNA work, oligonucleotide work</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>OXFORD ATAXIA CONSORTIUM</gtr:description><gtr:id>B27714C9-B1C5-4067-8366-BA6895FA6B02</gtr:id><gtr:impact>19789634</gtr:impact><gtr:outcomeId>k2P78kLHM7J-1</gtr:outcomeId><gtr:partnerContribution>Avenues for research work</gtr:partnerContribution><gtr:piContribution>Evaluation of RNAi therapies for SCA7</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>Oxford Psychiatry collaboration</gtr:description><gtr:id>63089A4E-0FE7-412D-BFDC-07C0048A17E9</gtr:id><gtr:impact>20828614</gtr:impact><gtr:outcomeId>NSptzmeBmR1-1</gtr:outcomeId><gtr:partnerContribution>New research avenues</gtr:partnerContribution><gtr:piContribution>Generation of RNAi silencing vectors for psychiatric research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Achtion Duchenne Charity</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>3E35191E-E2CB-4C20-B576-C9C6253D7124</gtr:id><gtr:impact>Advisory activity

Key strategic decisions made</gtr:impact><gtr:outcomeId>CAA0D718CFF</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Muscular dystrophy campaign</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>D52AB6A5-C0A9-4C95-88FA-E688C34734A0</gtr:id><gtr:impact>Advisory activity

Key strategic decisions</gtr:impact><gtr:outcomeId>F9ECF03E45B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ATAXIA UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D7E4D37F-0BCB-4D7A-91D2-7DDF83FA6C89</gtr:id><gtr:impact>TALK TO RESEARCHERS, PATIENTS, POLICY MAKERS

EDUCATION, FURTHER DISCUSSIONS</gtr:impact><gtr:outcomeId>dZBPh1zUGUt</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne Charity</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>5ACF5941-9589-4FED-9604-531632D5FD5E</gtr:id><gtr:impact>Talk to general public and patients with muscle disease

Better public understanding</gtr:impact><gtr:outcomeId>2A0ACDA62BA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Action Duchenne Charity</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>F54024F6-7AE0-4152-8033-4AC4B9A6F657</gtr:id><gtr:impact>Article

N/A</gtr:impact><gtr:outcomeId>859ED62ED65</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Muscular Dystrophy Campaign</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>0C06BEA9-5272-4911-A73F-52F5A4B5112E</gtr:id><gtr:impact>Article

na</gtr:impact><gtr:outcomeId>RnfVWACDLxQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parliament lobby</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>AF04338F-78A2-470A-A115-B68973E44457</gtr:id><gtr:impact>Public meeting wiht MPs

Better understanding and awareness of muscle disease and muscle disease therapies</gtr:impact><gtr:outcomeId>93ABBA6FE0B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PARKINSON'S UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C18B3926-D87F-40CB-9F0E-DF5E8AC364D4</gtr:id><gtr:impact>INFLUENCING RESEARCH POLICY AND FUNDING DECISIONS FOR PARKINSON'S DISEASE RESEARCH

CHANGES IN POLICY
NEW FUNDING INITIATIVES</gtr:impact><gtr:outcomeId>dhWQNgfdeSf</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>E4D7CCF2-361B-4E41-86B9-A5AE7D4416C6</gtr:id><gtr:outcomeId>64F9166A9B80</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1650000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC PROGRAMME</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B75CB641-0CCF-4DDF-BF76-943BA9DB1FFA</gtr:id><gtr:outcomeId>X1SEMhuMAku0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WELLCOME HICF</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>0DB1BD40-DCA2-48DD-8BB3-B85D1F456470</gtr:id><gtr:outcomeId>Fqu4Keveus10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3200000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AFM PROGRAMME</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>AC508570-6CF0-45DE-B8E0-492D341249B7</gtr:id><gtr:outcomeId>tmY5bSSXd3z0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European training network</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B0327F49-F6EC-44AA-BCA7-9770AA865E92</gtr:id><gtr:impact>Recognition that better training of scientists and clinicians and muscle disease biology and therapy is necessary</gtr:impact><gtr:outcomeId>A3F0EEA08CE</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Action Duchenne</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>FC2A8AE2-CAB9-40BF-B316-9B1CA717459C</gtr:id><gtr:impact>Funding for muscular dystrophy research and care of DMD patients</gtr:impact><gtr:outcomeId>fPhWp1X8wuh</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Parkinson's UK Advisory Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>4D4A97CF-BB98-4C7A-8400-864BEA270536</gtr:id><gtr:impact>Research funding and research policy</gtr:impact><gtr:outcomeId>eLXK62daUnQ</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>TREAT-NMD</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>B92B8F67-E0D7-4622-A8EF-9D05AC9F7B45</gtr:id><gtr:impact>Clinical trials policy for european neuromuscular disease research</gtr:impact><gtr:outcomeId>KTaYs5acn2x</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CEE6BCD3-FE1A-48D9-A7CD-6BD8800660F6</gtr:id><gtr:title>Modulating the expression of disease genes with RNA-based therapy.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b519c98ece0d0c47d12b4e510c6a9518"><gtr:id>b519c98ece0d0c47d12b4e510c6a9518</gtr:id><gtr:otherNames>Wood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>8C1F6EEF059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28820516-1D69-4281-883C-3F01D7785412</gtr:id><gtr:title>In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85103be6c0a7ff70942dad56b4330959"><gtr:id>85103be6c0a7ff70942dad56b4330959</gtr:id><gtr:otherNames>Wang Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>fH1LGzpBXyk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED673781-DF2B-4A54-AEDC-ADA53AA23189</gtr:id><gtr:title>Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>PRvex6x9ZjQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BC56C2E-60A2-4BD3-B823-19F6A8CB080D</gtr:id><gtr:title>Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f82799396794e89283a9b0507792aa31"><gtr:id>f82799396794e89283a9b0507792aa31</gtr:id><gtr:otherNames>Ivanova GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>dLeHijVwdYL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B2C08CE-AD34-43AC-91B1-2B69CCE5BBAB</gtr:id><gtr:title>Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf93ecbab15b08ce52d70b1af9453dc"><gtr:id>baf93ecbab15b08ce52d70b1af9453dc</gtr:id><gtr:otherNames>Cirak S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>mMXubBZHu3P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82661EBF-2351-4765-AB38-277A986FAA2E</gtr:id><gtr:title>Diaphragm rescue alone prevents heart dysfunction in dystrophic mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/321e063cceeeaa3dbaebdbfe5918c9c4"><gtr:id>321e063cceeeaa3dbaebdbfe5918c9c4</gtr:id><gtr:otherNames>Crisp A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>eLPBGwRJsA8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2E61B67-C44E-49FE-A087-81D237899963</gtr:id><gtr:title>Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>D715520DB82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA125D1C-9B03-4EEE-94C6-F9F452F770C1</gtr:id><gtr:title>Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>mvCMnAjpboh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>765499AD-E906-49AB-A00F-B20DABBEDB15</gtr:id><gtr:title>Targeting RNA to treat neuromuscular disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d12a81c1a41c39038e9286100f8688e7"><gtr:id>d12a81c1a41c39038e9286100f8688e7</gtr:id><gtr:otherNames>Muntoni F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>Jw7eDifh9Kc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9B9E2D3-BCB2-42B8-B024-39AFE02776A6</gtr:id><gtr:title>Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>MBJaWU11GFu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B4B9268-AD63-4B6A-BD90-6576B0A110DE</gtr:id><gtr:title>A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bb9ddd1d52e8aedca258b33a5fc54b"><gtr:id>b7bb9ddd1d52e8aedca258b33a5fc54b</gtr:id><gtr:otherNames>Yin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>hBF54Z12Vjg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>067B12F6-131A-4524-9C6D-B4BFC962DF3D</gtr:id><gtr:title>Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4345298aa80f7aab384e189cb31b897"><gtr:id>f4345298aa80f7aab384e189cb31b897</gtr:id><gtr:otherNames>Kinali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>WDx1pSdZjzB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15D224E1-2AE0-475C-BFDF-390B4CA85979</gtr:id><gtr:title>Readministration of adenoviral gene delivery to dopamine neurons.</gtr:title><gtr:parentPublicationTitle>Neuroreport</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c1293458a78e955f5122e7394a4b200"><gtr:id>0c1293458a78e955f5122e7394a4b200</gtr:id><gtr:otherNames>Gonzalez SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0959-4965</gtr:issn><gtr:outcomeId>K9otBqw83Vc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10309136-40A2-49E8-AE81-2E71AB5AB149</gtr:id><gtr:title>Th1 cytokines are upregulated by adenoviral vectors in the brains of primed mice.</gtr:title><gtr:parentPublicationTitle>Neuroreport</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52978aff0115bb7c61e0962b640b7545"><gtr:id>52978aff0115bb7c61e0962b640b7545</gtr:id><gtr:otherNames>Lee MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-4965</gtr:issn><gtr:outcomeId>R9cMPFcgQxA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>692A0748-5811-460A-8EEA-048AF79CF52B</gtr:id><gtr:title>D-amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88f1f51fcbd873377fbc0243807e5763"><gtr:id>88f1f51fcbd873377fbc0243807e5763</gtr:id><gtr:otherNames>Burnet PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>RzKUnRQ1R5G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>187D33DA-8A19-463A-9328-5251E313FBF6</gtr:id><gtr:title>Identification of a novel muscle targeting peptide in mdx mice.</gtr:title><gtr:parentPublicationTitle>Peptides</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ab632260589a58159b24c524820efc5"><gtr:id>3ab632260589a58159b24c524820efc5</gtr:id><gtr:otherNames>Seow Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0196-9781</gtr:issn><gtr:outcomeId>c2bLFMtkai1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>797C0313-F788-4438-BF08-91848CEE6B44</gtr:id><gtr:title>Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0d31076f8584287002efea3d1eeb4f7"><gtr:id>a0d31076f8584287002efea3d1eeb4f7</gtr:id><gtr:otherNames>Jagannath A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>DAoEbAPtFj4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49ADB505-763B-4B33-945B-CDE5C879DB23</gtr:id><gtr:title>PNA-peptide conjugates as intracellular gene control agents.</gtr:title><gtr:parentPublicationTitle>Nucleic acids symposium series (2004)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f82799396794e89283a9b0507792aa31"><gtr:id>f82799396794e89283a9b0507792aa31</gtr:id><gtr:otherNames>Ivanova GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0261-3166</gtr:issn><gtr:outcomeId>498F0AABD73</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9D214D3-2EF3-4C4D-BFF1-30654BEC8FBA</gtr:id><gtr:title>Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a171f5f5d57d4c804abba7d89c8801a9"><gtr:id>a171f5f5d57d4c804abba7d89c8801a9</gtr:id><gtr:otherNames>Scholefield J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>LMutAeLDKm1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500822</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>